Poster Spotlight 5: Liquid Biomarkers in Breast Cancer—Driving Precision Medicine
Session Details
The text of the abstracts will be posted on Monday, November 24.
Moderator
Michail Ignatiadis, Institut Jules Bordet, Brussels, Belgium
Presentation numberPD5-01
Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+/HER2- early-stage breast cancer (LEADER)
Arielle J Medford, Mass General Cancer Center/Harvard Medical School, Boston, MA
Presentation numberPD5-02
5-year outcomes and ctdna findings in the clever trial targeting disseminated dormant tumor cells
Angela DeMichele, University of Pennsylvania, Philadelphia, PA
Presentation numberPD5-03
Deep Proteomics and AI Classifier for Early Breast Cancer Detection
Justin M. Drake, Astrin Biosciences, St. Paul, MN
Presentation numberPD5-05
Impact of circulating tumor DNA (ctDNA) surveillance on quality of life (QoL) for patients with early-stage breast cancer (EBC): prospective I-SURV study
Cheng Cheng, University of California, Los Angeles, CA
Presentation numberPD5-06
Discussant: Molecular Residual Disease
David Cescon, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Presentation numberPD5-07
Prospective Analysis of Circulating Tumor Cell Clearance and Dynamics with Adjuvant Radiotherapy in Locally Advanced Breast Cancer
Chelain R Goodman, UT MD Anderson Cancer Center, Houston, TX
Presentation numberPD5-08
Circulating Tumour DNA (ctDNA) Dynamics From Patients With ER+, HER2- Advanced Breast Cancer in the Phase 3 EMBER-3 Trial
Francois-Clement BIDARD, Institut Curie, Paris, France
Presentation numberPD5-09
Molecular features of response to palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial
Nicholas Turner, Institute of Cancer Research, London, United Kingdom
Presentation numberPD5-10
Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS)
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, NY
Presentation numberPS5-11
Ultrasensitive ctDNA Tracking Predicts Exceptional Response in HER2+ Metastatic Breast Cancer
Stefania Morganti, Dana Farber Cancer Institute, Boston, MA
Presentation numberPD5-12
Discussant: Identifying molecular and clinical factors related to recurrence and disease progression
Javier Pascual, Virgen de la Victoria University Hospital, Malaga, Spain